Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fisher, B.
Right arrow Articles by Dimitrov, N. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fisher, B.
Right arrow Articles by Dimitrov, N. V.

Journal of Clinical Oncology, Vol 15, 2483-2493, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18

B Fisher, A Brown, E Mamounas, S Wieand, A Robidoux, RG Margolese, AB Cruz Jr, ER Fisher, DL Wickerham, N Wolmark, A DeCillis, JL Hoehn, AW Lees and NV Dimitrov
Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Shadyside Hospital, PA, USA. nsabpbf@pitt.edu

PURPOSE: To determine whether preoperative doxorubicin and cyclophosphamide (AC) permits more lumpectomies to be performed and decreases the incidence of positive nodes in women with primary breast cancer. PATIENTS AND METHODS: Women (n = 1,523) were randomized to National Surgical Adjuvant Breast and Bowel Project (NSABP) B-18; 759 eligible patients received postoperative AC and 747, preoperative AC. The clinical size of breast and axillary tumors was determined before each of four cycles of AC and before surgery. Tumor response to preoperative therapy was clinically complete (cCR), partial (cPR), stable (cSD), or progressive disease (cPD). Tissue from patients with a cCR was evaluated for a pathologic complete response (pCR). RESULTS: Breast tumor size was reduced in 80% of patients after preoperative therapy; 36% had a cCR. Tumor size and clinical nodal status were independent predictors of cCR. Twenty-six percent of women with a cCR had a pCR. Clinical nodal response occurred in 89% of node-positive patients: 73% had a cCR and 44% of those had a pCR. There was a 37% increase in the incidence of pathologically negative nodes. Before randomization, lumpectomy was proposed for 86% of women with tumors < or = 2 cm, 70% with tumors 2.1 to 5.0 cm, and 3% with tumors > or = 5.1 cm. Clinical tumor size and nodal status influenced the physician's decision. Overall, 12% more lumpectomies were performed in the preoperative group; in women with tumors > or = 5.1 cm, there was a 175% increase. CONCLUSION: Preoperative therapy reduced the size of most breast tumors and decreased the incidence of positive nodes. The greatest increase in lumpectomy after preoperative therapy occurred in women with tumors > or = 5 cm, since women with tumors less than 5 cm were already lumpectomy candidates. Preoperative therapy should be considered for the initial management of breast tumors judged too large for lumpectomy.


This article has been cited by other articles:


Home page
 Cancer Res.Home page
B. Fisher
Biological Research in the Evolution of Cancer Surgery: A Personal Perspective
Cancer Res., December 15, 2008; 68(24): 10007 - 10020.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
K. E. Kilbride, M. C. Lee, A. V. Nees, V. M. Cimmino, K. M. Diehl, M. S. Sabel, D. F. Hayes, A. F. Schott, C. G. Kleer, A. E. Chang, et al.
Axillary Staging Prior to Neoadjuvant Chemotherapy for Breast Cancer: Predictors of Recurrence
Ann. Surg. Oncol., November 1, 2008; 15(11): 3252 - 3258.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
C. E. Loo, H. J. Teertstra, S. Rodenhuis, M. J. van de Vijver, J. Hannemann, S. H. Muller, M.-J. V. Peeters, and K. G. A. Gilhuijs
Dynamic Contrast-Enhanced MRI for Prediction of Breast Cancer Response to Neoadjuvant Chemotherapy: Initial Results
Am. J. Roentgenol., November 1, 2008; 191(5): 1331 - 1338.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Berruti, M. P. Brizzi, D. Generali, M. Ardine, L. Dogliotti, P. Bruzzi, and A. Bottini
Presurgical Systemic Treatment of Nonmetastatic Breast Cancer: Facts and Open Questions
Oncologist, November 1, 2008; 13(11): 1137 - 1148.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Emmering, N. C. Krak, J. J. M. Van der Hoeven, M. D. Spreeuwenberg, J. W. R. Twisk, S. Meijer, H. M. Pinedo, and O. S. Hoekstra
Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology
Ann. Onc., September 1, 2008; 19(9): 1573 - 1577.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
J. S. Jeruss, E. A. Mittendorf, S. L. Tucker, A. M. Gonzalez-Angulo, T. A. Buchholz, A. A. Sahin, J. N. Cormier, A. U. Buzdar, G. N. Hortobagyi, and K. K. Hunt
Staging of Breast Cancer in the Neoadjuvant Setting
Cancer Res., August 15, 2008; 68(16): 6477 - 6481.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
X. Li, M. T. Lewis, J. Huang, C. Gutierrez, C. K. Osborne, M.-F. Wu, S. G. Hilsenbeck, A. Pavlick, X. Zhang, G. C. Chamness, et al.
Intrinsic Resistance of Tumorigenic Breast Cancer Cells to Chemotherapy
J Natl Cancer Inst, May 7, 2008; 100(9): 672 - 679.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. P. Mamounas
Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings
Ann. Surg. Oncol., March 1, 2008; 15(3): 691 - 703.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Gralow, J. A. Zujewski, and E. Winer
Preoperative Therapy in Invasive Breast Cancer: Reviewing the State of the Science and Exploring New Research Directions
J. Clin. Oncol., February 10, 2008; 26(5): 696 - 697.
[Full Text] [PDF]

Home page
 JCOHome page
P. Rastogi, S. J. Anderson, H. D. Bear, C. E. Geyer, M. S. Kahlenberg, A. Robidoux, R. G. Margolese, J. L. Hoehn, V. G. Vogel, S. R. Dakhil, et al.
Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
J. Clin. Oncol., February 10, 2008; 26(5): 778 - 785.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. A. Buchholz, C. D. Lehman, J. R. Harris, B. A. Pockaj, N. Khouri, N. F. Hylton, M. J. Miller, T. Whelan, L. J. Pierce, L. J. Esserman, et al.
Statement of the Science Concerning Locoregional Treatments After Preoperative Chemotherapy for Breast Cancer: A National Cancer Institute Conference
J. Clin. Oncol., February 10, 2008; 26(5): 791 - 797.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Gralow, H. J. Burstein, W. Wood, G. N. Hortobagyi, L. Gianni, G. von Minckwitz, A. U. Buzdar, I. E. Smith, W. F. Symmans, B. Singh, et al.
Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable Disease
J. Clin. Oncol., February 10, 2008; 26(5): 814 - 819.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. J. Solin, S. G. Orel, W.-T. Hwang, E. E. Harris, and M. D. Schnall
Relationship of Breast Magnetic Resonance Imaging to Outcome After Breast-Conservation Treatment With Radiation for Women With Early-Stage Invasive Breast Carcinoma or Ductal Carcinoma in Situ
J. Clin. Oncol., January 20, 2008; 26(3): 386 - 391.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. S. Jeruss, E. A. Mittendorf, S. L. Tucker, A. M. Gonzalez-Angulo, T. A. Buchholz, A. A. Sahin, J. N. Cormier, A. U. Buzdar, G. N. Hortobagyi, and K. K. Hunt
Combined Use of Clinical and Pathologic Staging Variables to Define Outcomes for Breast Cancer Patients Treated With Neoadjuvant Therapy
J. Clin. Oncol., January 10, 2008; 26(2): 246 - 252.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. Hudis and S. Modi
Preoperative Chemotherapy for Breast Cancer: Miracle or Mirage?
JAMA, December 12, 2007; 298(22): 2665 - 2667.
[Full Text] [PDF]

Home page
 The OncologistHome page
J. C. Boughey, R. J. Gonzalez, E. Bonner, and H. M. Kuerer
Current Treatment and Clinical Trial Developments for Ductal Carcinoma In Situ of the Breast
Oncologist, November 1, 2007; 12(11): 1276 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. M. Layman, D. G. Thomas, K. A. Griffith, J. B. Smerage, M. A. Helvie, M. A. Roubidoux, K. M. Diehl, L. A. Newman, M. S. Sabel, J. A. Hayman, et al.
Neoadjuvant Docetaxel and Capecitabine and the Use of Thymidine Phosphorylase as a Predictive Biomarker in Breast Cancer
Clin. Cancer Res., July 15, 2007; 13(14): 4092 - 4097.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
B. P. Coudert, R. Largillier, L. Arnould, P. Chollet, M. Campone, D. Coeffic, F. Priou, J. Gligorov, X. Martin, V. Trillet-Lenoir, et al.
Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2 Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial
J. Clin. Oncol., July 1, 2007; 25(19): 2678 - 2684.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C Natoli, E Cianchetti, N Tinari, D Angelucci, A Grassadonia, M Zilli, C Ficorella, E Ricevuto, S Grossi, M De Tursi, et al.
A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer
Ann. Onc., June 1, 2007; 18(6): 1015 - 1020.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. G. Steger, A. Galid, M. Gnant, B. Mlineritsch, A. Lang, C. Tausch, M. Rudas, R. Greil, C. Wenzel, C. F. Singer, et al.
Pathologic Complete Response With Six Compared With Three Cycles of Neoadjuvant Epirubicin Plus Docetaxel and Granulocyte Colony-Stimulating Factor in Operable Breast Cancer: Results of ABCSG-14
J. Clin. Oncol., May 20, 2007; 25(15): 2012 - 2018.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al.
Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography
J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. Loibl, G. von Minckwitz, G. Raab, J.-U. Blohmer, S. D. Costa, B. Gerber, H. Eidtmann, S. Petrich, J. Hilfrich, C. Jackisch, et al.
Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial
Ann. Surg. Oncol., November 1, 2006; 13(11): 1434 - 1442.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Moschos, H. D. Edington, S. R. Land, U. N. Rao, D. Jukic, J. Shipe-Spotloe, and J. M. Kirkwood
Neoadjuvant Treatment of Regional Stage IIIB Melanoma With High-Dose Interferon Alfa-2b Induces Objective Tumor Regression in Association With Modulation of Tumor Infiltrating Host Cellular Immune Responses
J. Clin. Oncol., July 1, 2006; 24(19): 3164 - 3171.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Sparano, S. Moulder, A. Kazi, L. Vahdat, T. Li, C. Pellegrino, P. Munster, M. Malafa, D. Lee, S. Hoschander, et al.
Targeted Inhibition of Farnesyltransferase in Locally Advanced Breast Cancer: A Phase I and II Trial of Tipifarnib Plus Dose-Dense Doxorubicin and Cyclophosphamide
J. Clin. Oncol., July 1, 2006; 24(19): 3013 - 3018.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
P. F. Escobar, R. J. Patrick, L. A. Rybicki, D. Hicks, D. E. Weng, and J. P. Crowe
Prognostic Significance of Residual Breast Disease and Axillary Node Involvement for Patients Who Had Primary Induction Chemotherapy for Advanced Breast Cancer
Ann. Surg. Oncol., June 1, 2006; 13(6): 783 - 787.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum
Primary Systemic Therapy of Breast Cancer
Oncologist, June 1, 2006; 11(6): 574 - 589.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
I. L. Wapnir, S. J. Anderson, E. P. Mamounas, C. E. Geyer Jr, J.-H. Jeong, E. Tan-Chiu, B. Fisher, and N. Wolmark
Prognosis After Ipsilateral Breast Tumor Recurrence and Locoregional Recurrences in Five National Surgical Adjuvant Breast and Bowel Project Node-Positive Adjuvant Breast Cancer Trials
J. Clin. Oncol., May 1, 2006; 24(13): 2028 - 2037.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. D. Bear, S. Anderson, R. E. Smith, C. E. Geyer Jr, E. P. Mamounas, B. Fisher, A. M. Brown, A. Robidoux, R. Margolese, M. S. Kahlenberg, et al.
Sequential Preoperative or Postoperative Docetaxel Added to Preoperative Doxorubicin Plus Cyclophosphamide for Operable Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol., May 1, 2006; 24(13): 2019 - 2027.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Kaufmann, G. N. Hortobagyi, A. Goldhirsch, S. Scholl, A. Makris, P. Valagussa, J.-U. Blohmer, W. Eiermann, R. Jackesz, W. Jonat, et al.
Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
J. Clin. Oncol., April 20, 2006; 24(12): 1940 - 1949.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Guarneri, K. Broglio, S.-W. Kau, M. Cristofanilli, A. U. Buzdar, V. Valero, T. Buchholz, F. Meric, L. Middleton, G. N. Hortobagyi, et al.
Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors
J. Clin. Oncol., March 1, 2006; 24(7): 1037 - 1044.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Roentgenol.Home page
M. Tozaki, T. Kobayashi, S. Uno, K. Aiba, H. Takeyama, H. Shioya, I. Tabei, Y. Toriumi, M. Suzuki, and K. Fukuda
Breast-Conserving Surgery After Chemotherapy: Value of MDCT for Determining Tumor Distribution and Shrinkage Pattern
Am. J. Roentgenol., February 1, 2006; 186(2): 431 - 439.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Gianni, J. Baselga, W. Eiermann, V. Guillem Porta, V. Semiglazov, A. Lluch, M. Zambetti, D. Sabadell, G. Raab, A. Llombart Cussac, et al.
Feasibility and Tolerability of Sequential Doxorubicin/Paclitaxel Followed by Cyclophosphamide, Methotrexate, and Fluorouracil and Its Effects on Tumor Response as Preoperative Therapy
Clin. Cancer Res., December 15, 2005; 11(24): 8715 - 8721.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. W. Moon, S. Y. Rha, H. C. Jeung, W. I. Yang, C. O. Suh, and H. C. Chung
Neoadjuvant chemotherapy with infusional 5-fluorouracil, adriamycin and cyclophosphamide (iFAC) in locally advanced breast cancer: an early response predicts good prognosis
Ann. Onc., November 1, 2005; 16(11): 1778 - 1785.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. Cianfrocca and W. J. Gradishar
Controversies in the Therapy of Early Stage Breast Cancer
Oncologist, November 1, 2005; 10(10): 766 - 779.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Cristofanilli, A. Gonzalez-Angulo, and G. Hortobagyi
In Reply:
J. Clin. Oncol., September 20, 2005; 23(27): 6796 - 6797.
[Full Text] [PDF]

Home page
 Ann OncolHome page
S. Chua, I. E. Smith, R. P. A'Hern, G. A. Coombes, T. F. Hickish, A. C. Robinson, R. W. Laing, M. E. R. O'Brien, S. R. Ebbs, A. Hong, et al.
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2)
Ann. Onc., September 1, 2005; 16(9): 1435 - 1441.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. Frasci, G. D'Aiuto, P. Comella, R. Thomas, G. Botti, M. Di Bonito, M. D'Aiuto, G. Romano, M. R. Rubulotta, G. Comella, et al.
A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study
Ann. Onc., August 1, 2005; 16(8): 1268 - 1275.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Arpino, H.L. Weiss, G.M. Clark, S.G. Hilsenbeck, and C.K. Osborne
Hormone Receptor Status of a Contralateral Breast Cancer Is Independent of the Receptor Status of the First Primary in Patients Not Receiving Adjuvant Tamoxifen
J. Clin. Oncol., July 20, 2005; 23(21): 4687 - 4694.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al.
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study
J. Clin. Oncol., May 1, 2005; 23(13): 2988 - 2995.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. von Minckwitz, G. Raab, A. Caputo, M. Schutte, J. Hilfrich, J. U. Blohmer, B. Gerber, S. D. Costa, E. Merkle, H. Eidtmann, et al.
Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast Group
J. Clin. Oncol., April 20, 2005; 23(12): 2676 - 2685.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. P. Mamounas, A. Brown, S. Anderson, R. Smith, T. Julian, B. Miller, H. D. Bear, C. B. Caldwell, A. P. Walker, W. M. Mikkelson, et al.
Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Breast Cancer: Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27
J. Clin. Oncol., April 20, 2005; 23(12): 2694 - 2702.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. A. Newman and H. M. Kuerer
Advances in Breast Conservation Therapy
J. Clin. Oncol., March 10, 2005; 23(8): 1685 - 1697.
[Full Text] [PDF]

Home page
 JCOHome page
A. Hamilton and G. Hortobagyi
Chemotherapy: What Progress in the Last 5 Years?
J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J. S. Jeruss, D. J. Winchester, S. F. Sener, E. M. Brinkmann, M. M. Bilimoria, E. Barrera Jr., E. Alwawi, A. Nickolov, G. M. Schermerhorn, and D. J. Winchester
Axillary Recurrence After Sentinel Node Biopsy
Ann. Surg. Oncol., January 1, 2005; 12(1): 34 - 40.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. von Minckwitz, J.-U. Blohmer, G. Raab, A. Lohr, B. Gerber, G. Heinrich, H. Eidtmann, M. Kaufmann, J. Hilfrich, C. Jackisch, et al.
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study
Ann. Onc., January 1, 2005; 16(1): 56 - 63.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Dieras, P. Fumoleau, G. Romieu, M. Tubiana-Hulin, M. Namer, L. Mauriac, J.-P. Guastalla, E. Pujade-Lauraine, P. Kerbrat, P. Maillart, et al.
Randomized Parallel Study of Doxorubicin Plus Paclitaxel and Doxorubicin Plus Cyclophosphamide As Neoadjuvant Treatment of Patients With Breast Cancer
J. Clin. Oncol., December 15, 2004; 22(24): 4958 - 4965.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Taghian, J.-H. Jeong, E. Mamounas, S. Anderson, J. Bryant, M. Deutsch, and N. Wolmark
Patterns of Locoregional Failure in Patients With Operable Breast Cancer Treated by Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen and Without Radiotherapy: Results From Five National Surgical Adjuvant Breast and Bowel Project Randomized Clinical Trials
J. Clin. Oncol., November 1, 2004; 22(21): 4247 - 4254.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
S. Meisamy, P. J. Bolan, E. H. Baker, R. L. Bliss, E. Gulbahce, L. I. Everson, M. T. Nelson, T. H. Emory, T. M. Tuttle, D. Yee, et al.
Neoadjuvant Chemotherapy of Locally Advanced Breast Cancer: Predicting Response with in Vivo 1H MR Spectroscopy--A Pilot Study at 4 T
Radiology, November 1, 2004; 233(2): 424 - 431.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. F. Lebowitz, J. Eng-Wong, S. M. Swain, A. Berman, M. J. Merino, C. K. Chow, D. Venzon, F. Zia, D. Danforth, E. Liu, et al.
A Phase II Trial of Neoadjuvant Docetaxel and Capecitabine for Locally Advanced Breast Cancer
Clin. Cancer Res., October 15, 2004; 10(20): 6764 - 6769.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
E. P. Mamounas
Tailoring Loco-Regional Therapy with Neoadjuvant Chemotherapy: Another Step in the Right Direction
Ann. Surg. Oncol., October 1, 2004; 11(10): 888 - 891.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. Modlich, H.-B. Prisack, M. Munnes, W. Audretsch, and H. Bojar
Immediate Gene Expression Changes After the First Course of Neoadjuvant Chemotherapy in Patients with Primary Breast Cancer Disease
Clin. Cancer Res., October 1, 2004; 10(19): 6418 - 6431.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Colleoni, G. Viale, D. Zahrieh, G. Pruneri, O. Gentilini, P. Veronesi, R. D. Gelber, G. Curigliano, R. Torrisi, A. Luini, et al.
Chemotherapy Is More Effective in Patients with Breast Cancer Not Expressing Steroid Hormone Receptors: A Study of Preoperative Treatment
Clin. Cancer Res., October 1, 2004; 10(19): 6622 - 6628.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S.-J. Kim, S.-k. Kim, E. S. Lee, J. Ro, and S. h. Kang
Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy
Ann. Onc., September 1, 2004; 15(9): 1352 - 1357.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Zhu, L. W. C. Chow, W. T. Y. Loo, X.-Y. Guan, and M. Toi
Her2/neu Expression Predicts the Response to Antiaromatase Neoadjuvant Therapy in Primary Breast Cancer: Subgroup Analysis from Celecoxib Antiaromatase Neoadjuvant Trial
Clin. Cancer Res., July 15, 2004; 10(14): 4639 - 4644.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.